![Daniel Chevallard](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Daniel Chevallard
Directeur Financier/CFO chez
Viracta Subsidiary, Inc.
Fortune : 67 136 $ au 31/08/2026
Profil
Daniel R.
Chevallard is currently Chief Financial Officer at Viracta Subsidiary, Inc. since 2019 and Chief Financial Officer at LENZ Therapeutics, Inc. since 2024.
Former positions include Controller & Senior Director-Finance at Prometheus Laboratories, Inc., Chief Financial Officer & Secretary at Sunesis Pharmaceuticals, Inc., Chief Financial & Accounting Officer at Regulus Therapeutics, Inc. from 2017 to 2019, and Secretary, Chief Operating & Financial Officer at Viracta Therapeutics, Inc. from 2021 to 2024.
Education includes undergraduate studies at the University of San Diego.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,04 % | 27/03/2026 | 12 886 ( 0,04 % ) | 67 136 $ | 31/08/2026 |
Postes actifs de Daniel Chevallard
| Sociétés | Poste | Début |
|---|---|---|
Viracta Subsidiary, Inc.
 Viracta Subsidiary, Inc. BiotechnologyHealth Technology Develops proprietary viral gene activation therapy to address cancers associated with the epstein-barr virus | Directeur Financier/CFO | 01/07/2019 |
Anciens postes connus de Daniel Chevallard
| Sociétés | Poste | Fin |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Directeur Financier/CFO | 20/03/2024 |
| REGULUS THERAPEUTICS INC. | Directeur Financier/CFO | 26/07/2019 |
| VIRACTA THERAPEUTICS, INC. | Directeur Financier/CFO | - |
Prometheus Laboratories, Inc.
 Prometheus Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel pharmaceutical and diagnostic products | Directeur Financier/CFO | - |
Formation de Daniel Chevallard
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
52
Relations au 1er degré
6
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Sunesis Pharmaceuticals, Inc.
 Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops oncology therapeutics for treatment of solid and hematologic cancers | Health Technology |
University of San Diego
 University of San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prometheus Laboratories, Inc.
Prometheus Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel pharmaceutical and diagnostic products | Health Technology |
Regulus Therapeutics, Inc.
 Regulus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that engages in discovering and developing of drugs | Health Technology |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Develops proprietary viral gene activation therapy to address cancers associated with the epstein-barr virus | Health Technology |
Viracta Therapeutics, Inc.
 Viracta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for virus-associated cancers | Health Technology |
